Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



#### SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 9989)

# ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Board )

. (	Company	<b>Hepalink</b>	)			-
	3	1, 2023 (	Reporting Peri	oup , w iod 2022.	ve , our Year ),	us)
RESUL	TS HIGHLIG	HTS				
1.		5,431.0	(2022	7,15	1.0	
2.	855.4	(2022 2023,		36.4	). Mar	
	1,7 6.3	(2022			326.5 % (2022	),
32	2.5%).	23			76 (2022 ₩	. <b>S</b>
3.	₩ 17.3° ₩ 855.4	40. % (2022 32.0°	(2022 %),	2,2	0.2	,
4.	2, 7 .0	(2022	3,210.5	· ·		₩/
5.	2,673.8		. 💆		1,307.3	(2022
6.	1,084.1	)		<b>M</b> /	67.0	(2022
7.	·			<b>⊠</b> ,	783.3 727.4	). (2022

#### CONSOLIDATED STATEMENT OF PROFIT OR LOSS

Year ended December 31, 2023

	Notes	2023 RMB'000	2022 RMB'000 ( )*
REVENUE	4	5,430,974 (4,490,078)	7,151,03 (4,860,850)
Gross profit		940,896	2,2 0,18
	5	222,317 (517,416) (674,546)	207,431 (518,502) (742,461)
<b>⊠</b> ′		(22,548) (68,155)	(61,067)
,		(44,515)	
	6	(9,801) (78,528) (228,087) (447,951)	(1,648) (245,62) (8,462)
(LOSS)/PROFIT BEFORE TAX	7	(928,334)	82 ,851
/( )	8	126,175	(114,816)
(LOSS)/PROFIT FOR THE YEAR		(802,159)	715,035
⊠v -		(783,258) (18,901)	727,425 (12,3 0)
(LOSS)/EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	9		
· ( )/		RMB(0.53)	0.50

<sup>\*</sup> Details of restatement are set out in note 2.2 on page 23

#### CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Year ended December 31, 2023

	2023 RMB'000	2022 RMB'000
(LOSS)/PROFIT FOR THE YEAR	(802,159)	715,035
OTHER COMPREHENSIVE INCOME		
( )		
	51,000 (6,192)	260, 77 (13,481)
	44,808	247,4 6
<b>₩</b>		
	(9,234)	(5,554)
. ( )/	(2,592)	67,688
( )/ <u>₩</u>	(11,826)	62,134
,	32,982	30 ,630
( )/ ,	(769,177)	1,024,665
⊠v _	(750,324) (18,853)	1,036,305 (11,640)

#### CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at December 31, 2023

NON-CURRENT ASSETS		Notes	31 December 2023 <i>RMB'000</i>	31 2022 RMB'000 ( )*	2022 RMB'000 ( )*
220,883	NON-CURRENT ASSETS				
■ 2,322,375 2,350, 2 2,152,201 389,423 462,08 472,6 1,004,046 8,386 1,146,465    503,565 507,146 474,885 1,006,367 67,576 6,500 320,503 141,475 123,17 203,865 224,48 206,016	,				
389,423	·		,		,
1,004,046	MAT .		, ,		
1,006,367   67,576   6,500     320,503   141,475   123,1 7     203,865   224, 48   206,016     8,599,148   8,343,71   8,338,75     8,338,75     10   1,263,584   1,606,211   1,525,20     10,947   1,534   14, 3     364,429   507,405   566,687     45,371   44,833   44,088     414,184   1,311,633   80, 0     - 10   248     80   6,388   11,581     85,918   74,684   1,440,000     1,765,645   1,31 ,707   1,47 ,633     10,604,269   12,472,311   10,770,8 7     CURRENT LIABILITIES   11   302,223   427,433   385,787     388   497,560   545,512   608,72     362,052   428,218   377,814     4,763   37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     303,04,575   4,020,784   3,268,166     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     3,24,575   4,020,784   3,268,166     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,223     4,403   5, 02   6,				,	,
1,006,367   67,576   6,500     320,503			503 565	507 146	171 885
320,503   141,475   123,1 7			,		
CURRENT ASSETS    10   1,263,584   1,606,211   1,525,20     10,947   1,534   14, 3     364,429   507,405   566,687     45,371   44,833   44,088     414,184   1,311,633   80, 0     -	•			,	
CURRENT ASSETS    10	÷				
10	<del>-</del> .		8,599,148	8,343,71	8,338,75
10	CUDDENIT ACCETS				
10	CURRENT ASSETS		6 654 111	6.843 06	4 707 54
10,947   1,534   14, 3     364,429   507,405   566,687     45,371   44,833   44,088     414,184   1,311,633   80, 0     -   10   248     80   6,388   11,581     85,918   74,684   1,440,000     1,765,645   1,31 ,707   1,47 ,633     10,604,269   12,472,311   10,770,8 7     10,770,8 7     11   302,223   427,433   385,787     388     497,560   545,512   608,72     362,052   428,218   377,814     -   3,624,575   4,020,784   3,268,166     157,178   112,257   112, 7     4,403   5, 02   6,223     37,803   35,6 0   31,754     31,544   362,052   428,218     37,803   35,6 0   31,754     362,052   428,218   377,814     4,403   5, 02   6,223     37,803   35,6 0   31,754     4,403   5,02   6,223     37,803   35,6 0   31,754     4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     362,457   4,403   5,02   6,223     37,803   35,6 0   31,754     37,803   35,6 0   31,754     37,803   35,6 0   31,754     37,803   37,803   35,6 0     37,803   37,803   37,804     37,803   37,804     37,803   37,804     37,803   37,804     37,804   37,804     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805     37,805   37,805		10			
## 45,371					
## A14,184	,				
Total Property					
80 6,388 11,581 85,918 74,684 1,440,000 1,765,645 1,31,707 1,47,633  10,604,269 12,472,311 10,770,8 7  CURRENT LIABILITIES  11 302,223 427,433 385,787 388 497,560 545,512 608,72 362,052 428,218 377,814 - 3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754			414,184		
85,918 74 ,684 1,440,000 1,765,645 1,31 ,707 1,47 ,633  10,604,269 12,472,311 10,770,8 7  CURRENT LIABILITIES  11 302,223 427,433 385,787 388 497,560 545,512 608,72 362,052 428,218 377,814 - 3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754	•		80		
Total Property of the content of th					
CURRENT LIABILITIES  11 302,223 427,433 385,787  388  497,560 545,512 608,72  362,052 428,218 377,814  - 3,624,575 4,020,784 3,268,166  157,178 112,257 112, 7  4,403 5, 02 6,223  37,803 35,6 0 31,754			1,765,645	1,31 ,707	1,47 ,633
11 302,223 427,433 385,787 388 497,560 545,512 608,72 362,052 428,218 377,814 3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754			10,604,269	12,472,311	10,770,8 7
11 302,223 427,433 385,787 388 497,560 545,512 608,72 362,052 428,218 377,814 3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754	CURRENT LIABILITIES				
388 497,560 545,512 608,72 362,052 428,218 377,814  3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754	· · · · · · · · · · · · · · · · · · ·	11	302,223	427,433	385,787
362,052 428,218 377,814 3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754			388	,	,
3,624,575 4,020,784 3,268,166 157,178 112,257 112, 7 4,403 5, 02 6,223 37,803 35,6 0 31,754					
157,178       112,257       112, 7         4,403       5, 02       6,223         37,803       35,6 0       31,754	_				
4,403       5, 02       6,223         37,803       35,6 0       31,754	- May				
	•				
<b>4,986,182</b> 5,575,7 6 4,7 1,470				33,0 0	31,/34
4,700,102 3,373,7 0 4,7 1,470			/ 08K 187	5 575 7 6	47 1 470
	•		7,700,102	3,373,7 0	4,/ 1,4/0

<sup>\*</sup> Details of restatement are set out in note 2.2 on page 23


#### CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at December 31, 2023

		31 December	31	1
	Notes	2023 RMB'000	2022 RMB'000 ( )*	2022 RMB'000 ( )*
NET CURRENT ASSETS		5,618,087	6,8 6,515	5, 7 ,427
TOTAL ASSETS LESS CURRENT LIABILITIES		14,217,235	15,240,234	14,318,186
NON-CURRENT LIABILITIES				
- ₩		1,810,021	2,2 6,680	2,250,270
		30,426	32,547	16,673
		252,568	328, 20	275,358
- ( - <u>N</u> )/ 7 <u>N</u> ( - <u>N</u> )/	362 ☒ ☒	.6 0 0 687/	<b>M</b> (	- X)/ 368 X3:

#### MANAGEMENT DISCUSSION AND ANALYSIS

#### Overview



		, ⊠v		•
- -	,	•		
-		, ₩	<b>M</b> /	•
· 	,	•		• •
<u>.</u> <b>⊠</b> ⁄	,	. 📓		
	• ,	. –		
<b>⊠</b> ⁄		,		<b>M</b> /
2023.			Μ.	, , ,
2023, <b>№</b> ,	<b>5</b> 4/	5 , <b>⋈</b>	<b>⊠</b> ⁄ <b>⊠</b> ⁄	11,77
, · · -	,	,		,805
2023.		<u>.</u> <b>⊠</b> ⁄	,	•
	•	,		
•		2023.		•
2024	May – May	,	<b>S</b> €V	
, ₩			MAN .	855.4
M		,		
	-1	, <b>M</b>		
	V	, .		<b>33</b> /
	<b>.</b>	-	,	
•	,			. ( HighTide )
2023.			,	368.6
(2022 83.	)	<b>⊠</b> ⁄ ,	,	
				<b>5</b> 7
( <b>Tec</b>	chdow Italy ), ₩	<b>- ⊠</b> ⁄	15, 2024,	<b>⊠</b> ′ , <b>⊠</b> ′
`				
-			( 14-1	,
		11.74		
	14 2024,		,	y Incident ).
M 1) ( Mr. Li ),	14 2024,		,	y Incident ).
/			,	y Incident ).  y Incident ).  nzhen Leren ),
( Mr. Li ),	14 2024,		,	y Incident ).  y Incident ).  nzhen Leren ),
( Mr. Li ), 2)	14 2024, 8 ,80 ,600 (	11.74	,	y Incident ).  my  nzhen Leren ),  11.74
( Mr. Li ),	14 2024, 8 ,80 ,600 (		,	y Incident ).  M  nzhen Leren ),  11.74


**M**√ 7.6500, 2023, 5,431.0 24.1%. 783.3 (2022 387.0 841. ) ( 8th VBP), 2023, XX, ( **FDA** ), . ( Techdow USA ), . ( **CTTQ** ), **M** M XX Sales ( ) • ( )

### **Heparin Industrial Chain Business**

4,286.3 (2022 5,884.3 ).


X 2,673.8 1,307.3 (2022 24.1% **⋈** 30% 2023,


#### **CDMO Business**



#### **Innovative Drugs and Innovative Business**

, , ,	, - 125	
₩/	•	<b>.</b> <b>⊠</b>
,		<u>·</u>
( ).	<u>M</u> , , , , ,	<b>⊠</b>
<b>№</b>	., ., . (	). 🗸 🖼
<b>AR-301 (Salvecin)</b> -301	1 ( )	•
	. ( <b>Aridis</b> )301 🗟	
<b>⊠</b> 4	·	( <b>EMA</b> ) ( -301)
65 🗟 -	· · · · · · · · · · · · · · · · · · ·	, ₩
		<b>≫</b> 4





#### **Financial Review**

#### Revenue

		For the year ended December 31,				Year-on-year
		2023	2023	2022	2022	increase/
		Sales amount	% of Revenue		% .	decrease
		RMB'000		RMB'000		(%)
		4,415,058	81.3%	6,012,848	84.1%	-26.6%
	•	2,979,030	54.9%	3,210,465	44. %	-7.2%
		1,307,343	24.1%	2,673,754	37.4%	-51.1%
(1)		128,685	2.4%	128,62	1.8%	0.0%
		966,952	17.8%	1,084,066	15.2%	-10.8%
(2)		48,964	0.9%	54,125	0.8%	5%
Total		5,430,974	100.0%	7,151,03	100%	-24.1%
					1,5 7.8	
4,415.1	,		1.3%			
,	<b>⊠</b> /	6,012.	84.1	1%	, ,	2022.
	•				22	-
Cost of sales						
	,			370.8		4,4 0.1
,	<b>M</b> √	4,860.	2	022.		•
						. , .
	<b>,</b> ₩					

### Gross Profit

For the year ended December 31,					
2023	2023	2022	2022		
G	Fross profit				
<b>Gross profit</b>	margin				
RMB'000	(%)	RMB'000	(%)		
693,525	15.7%	1,821,343	30.3%		
1,284,627	43.1%	1.132.402	35.3%		

#### Impairment losses on goodwill



Impairment losses on property, plant and equipment and other intangible assets 44.5

#### **Liquidity and Financial Resources**

Treasury Policies

**⋈**′, . 🔯 Liquidity and Financial Resources M 31, 2023, 1,765.6 31, 2022 1,31 .7 ). Capital Structure 31, 2023, 3,624.6 ( 31, 2022 4,020.8 1,810.0 31, 2022 2,2 6.7 ). Pledge of Assets 2, 31, 2023, 5.5 XX . ( 31, 2022 3,182.0 ). Contingent Liabilities 31, 2023, ( 31, 2022 ). Asset-liability Ratio 31, 2023, 1 ,203.4 31, 2022 20,816.0 , ( ), My 7,215.0 31, 2022 8,406.6 ). ) **M** 37.6% ( 31, 2022 40.4%).

# Interest Rate Risk

-			<b>⊠</b> ⁄ <b>⊠</b> ⁄		. ,
31, 2	2023,	. (	31, 2022	6.6% - 2.7%)	₩
Indebtedness					
				As at December 31, 2023 RMB'000	31, 2022 <i>RMB</i> '000
-			<b>⊠</b> 4′	5,434,596 128,220	6,317,464 146,43
				5,562,816	6,463, 03
				(80)	(6,388)
				5,562,736	6,3 4,515
<u>.</u> <b>⊠</b> /		,	-		<b>X</b>
				As at December 31, 2023 RMB'000	31, 2022 <i>RMB'000</i>
	. <b>⊠</b> / <b>∑</b>	<b>M</b> /		3,624,575 772,003 642,237 395,781	4,020,784 1,404,818 435,1 5 456,667
				5,434,596	6,317,464
1,403.0	31, 2		31, 2023	). 512.7 (	4,365. 31, 2023, 31, 2022
<b>⊠</b> /	556.0	(	31, 2022	2 603.4 )	

#### NOTES TO THE CONSOLIDATED FINANCIAL INFORMATION

December 31, 2023


1. **Corporate Information** 21, 1 8. PRC ) 0023 . ) 6, 2010. Hong Kong Stock Exchange ) ( 8, 2020. 8). .21 4724, 47/ , ... , 30 2.1 **Basis of Preparation** ( **IFRSs** ), (**⊠** (IASs) IASB ) ( ( **RMB** ) (000) ( Basis of consolidation 31, 2023. M

).

( ) ( ) ( ) () ( ) ( )

22

#### 2.2 Changes in Accounting Policies and Disclosures



, . .

1 2022. , () ₩ (

Impact on the consolidated statements of financial position:

#### Increase/(decrease)

	111	ici casci (acci casc	•)
	As at 31 December	31	1 .
	2023 RMB'000	2022 RMB'000	2022 RMB'000
Assets	2,244	1,826	1,47
<del>-</del> .	2,244	1,826	1,47
	2,244	1,826	1,47
	2,244	1,826	1,47
Equity ( )	2,244	1,826	1,47
. <b>⊠</b> 4	2,244	1,826	1,47
-			
	2,244	1,826	1,47

24

				For the y	Increase/(decrease) For the year ended 31 December	
				2023	2022	
				RMB'000	RMB'000	
				319	348	
				319	348	
				99		
<b>M</b>				418	348	
-						
				418	348	
		12				
	2023 2022.			<u>₩</u>	, 31	
( )	12			<b>33</b> /	-	
	_	<b>S</b>	•			
			, 	<b>,</b>		
		<b>⊠</b> ′	₩/	<b>M</b>	<i>,</i>	
	₩		•	₩		
	<b>⊠</b> ⁄	<b>⊠</b> ⁄	⊠v		-	
	. <b>№</b> /	<b>⊠</b> /				
₩.	<b>56</b> √ <b>56</b> √			⊠v	<b>⊠</b> / <b>⊠</b> /	
	-					

#### 3. Operating Segment Information

- ( )

#### For the year ended December 31, 2023

	Finished dose				
_	pharmaceutical				
Segments	products	API	CDMO	Others	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Segment revenue:					
	2,979,030	1,307,343	966,952	177,649	5,430,974
	3,469,110	2,137,584	1,309	270,601	5,878,604
	6,448,140	3,444,927	968,261	448,250	11,309,578
					(5,878,604)
•					5,430,974
Segment results:	1,224,118	(405,677)	213,038	59,932	1,091,411
					(150,515)
					222,317
					(517,416)
					(674,546)
					(22,548)
₩.					(68,155)
,					(9,801)
					(44,515)
					(78,528)
					(228,087)
					(447,951)
Group's loss before tax					(928,334)

#### For the year ended December 31, 2023 (continued)

Segments	Finished dose pharmaceutical products <i>RMB'000</i>	API RMB'000	CDMO RMB'000	Others RMB'000	Total RMB'000
Segment assets	4,888,040	11,710,207	2,392,778	1,152,181	20,143,206
					(6,149,428)
-					5,209,639
					19,203,417
Segment liabilities	2,846,630	3,822,929	421,666	2,684,939	9,776,164
					(7,390,598)
					4,829,474
					7,215,040
Other segment information					
,	3,859 50,921	28,520 104,098	68,490 84,492	44,150 138,337	145,019 377,848 1,004,046
	381,103	31,561	41,399	15,783	469,846

	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Segment revenue:					
	3,210,465	2,673,754	1,084,066	182,754	7,151,03
	2,468,477	3,36 ,777	2,213	435,821	6,276,288
	5,678, 42	6,043,531	1,086,27	618,575	13,427,327
					(6,276,288)

31, 2022 ( )

	RMB'000	<i>RMB'000</i>	<i>RMB</i> '000	RMB'000	<i>RMB</i> '000
Segment assets	4,272,831	12,057,357	2,573,751	1,16 ,4	20,073,438
					(5,442,142)
					6,184,734
					20,816,030
Segment liabilities	2,261,51	3,228, 71	467,235	2,677,328	8,635,053
					(6,703,7 8)
					6,475,310
					8,406,565
Other segment information					
	40.0	29 246	20 522	100	61.067
,	4,0 0 47,343	28,346 8 ,404	28,523 77,826	108 7,434	61,067 312,007 8 ,386
•	15,100	4 , 04	68,758	12,532	146,2 4

#### Geographical information

#### (a) Revenue from external customers

2023 RMB'000	2022 RMB'000
18,098	103,018
	1,387,152
	3,72 ,856
	641,478
1,121,726	1,28 ,535
5,430,974	7,151,03
	18,098 1,277,604 2,615,709 397,837 1,121,726

#### (b) Non-current assets

nber 31,	As at Decemb
2022	2023
RMB'000	RMB'000
2,705,525	2,878,234
3,610,134	3,356,795
12 ,267	126,362
282,5 6	407,322
6,727,522	6,768,713

<del>-</del>.

#### Information about major customers

-		31, 2023,	<b>⊠</b> /	
	, -		<b>⊠</b> ′	<b>₩</b>
<b>3</b>	. ,		10%	
-		31, 2022,		733,01 ,000
	-		10%	

#### 4. Revenue

#### Revenue from contracts with customers

()

#### For the year ended December 31, 2023

	Finished dose pharmaceutical				
Segments	products	API	CDMO	Others	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Types of goods or services					
-	2,979,030	1,307,343	_	128,685	4,415,058
	-	-	966,952	-	966,952
				48,964	48,964
	2,979,030	1,307,343	966,952	177,649	5,430,974
Timing of revenue recognition					
	2,979,030	1,307,343	-	128,685	4,415,058
	_	_	456,111	13,818	469,929
			510,841	35,146	545,987
	2,979,030	1,307,343	966,952	177,649	5,430,974

	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Types of goods or services					
	3,210,465	2,673,754	1 004 066	128,62	6,012,848
			1,084,066	54,125	1,084,066
	3,210,465	2,673,754	1,084,066	182,754	7,151,03
Timing of revenue recognition					
	3,210,465	2,673,754		128,62	6,012,848
			320,17 763,887	20,207 33, 18	340,386 7 7,805
	3,210,465	2,673,754	1,084,066	182,754	7,151,03

	₩	<b>⊠</b> ′	-	-		
	₩	-				
					2023	2022
					RMB'000	RMB'000
		<b>⊠</b> /				
		MAN .	-			
	-				17,724	10,585
				_	423,216	407,67
					440,940	119 261
				=	<del>440,940</del>	418,264
( )						
( )		,			. <b>Sa</b> r	
	Sale of products					
				<b>3</b>		
	•					
	CDMO services					
			, .			
	<b>,</b> -		₩	1	5,	
	-		-		·	
		,				
		-				,
		,				-
		,	2.1	Mar		(.
	-	)	31	DOM/		
					2023	2022
					RMB'000	RMB'000
	×				493,767	652,130
	X X			=		
					<b>⊠</b> /	•
				<b>₩</b>	**	· · · · · · · · · · · · · · · · · · ·

#### 5. Other Income and Gains

Other income and Gams			
		2023 RMB'000	2022 RMB'000
Other income		39,521	54,13
*		2,672	4,744
**		19,343	33, 63
		36,433	7,107
	_	97,969	, 53
	_		
Other gains		85,867	186,331
/( )		1,014	(5,624)
. /( ),		17,724	(74,831)
		(86)	(26,86)
,	-	(1,678)	(2,760)
		7,265	21,771
	_	14,242	,460
	_	124,348	107,478
	_	222,317	207,431
*	_		
	<b>⊠</b> /		
**			
	-	<b>Sa</b> v	<b>⊠</b> /
	, ⊠′		,
	,		,
			. 🖼
		<b>M</b> ⁄	. 1231

35

#### 6. Finance Costs

×

2022 RMB'000	2023 RMB'000		
160, 12	185,053	₩.	
6 ,327	33,342		
5,003	4,824		
10,387	4,868		
245,62	228,087		
		Profit before Tax	7.
	)	,	, ·
2022	2023		
RMB'000	RMB'000		
Time ooo			
4,1 1,405	3,721,533		
66 ,445	768,545		
21 , 70	283,414	,	
38,741	38,341	<b>-</b>	
53,2 6	56,093		
252,142	182,433	*	
	68,155	89∕	
	44,515	,	
6,010	8,640	,	
		, ( ,	
654,005	648,760	. ):	
03 1,003	0.10,7.00	· , &	
120,378	95,615	<u>, , , , , , , , , , , , , , , , , , , </u>	
774,383	744,375		

						2023 RMB'000	2022 RMB'000
						3,749	2,488
						(39,521)	(54,13)
						228,087	245,62
						(36,433)	(7,107)
		(	)/ ,			(85,867)	(186,331)
(	)/				-	(1,014)	5,624
	. (	)/ )/		-		86	26,86
	. (	)/				(17,724)	74,831
				,	-	1,678	2,760
						(7,265)	(21,771)
X.	- 🖼					855,380	36,434
***						9,801	
						712	48,858
		,				21,836	12,20
						22,548	61,067

#### 8. Income Tax (Credit)/Expense

9.

,		₩/	
		2023 RMB'000	2022 RMB'000 ( )
		60,356 35,960	56,733 0,431
<b>8</b>		10,780 4,357	12,638 (1,338)
		111,453	158,464
		(148,044)	(2,873)
<b>™</b>		(46,882) (42,702)	(41,162) 387
		(237,628)	(43,648)
( )/		(126,175)	114,816
(Loss)/Earnings per Share	Attributable to Ordinary Equi	ity Holders of the Paren	ıt
	. ,	<b>⊠</b> ⁄	
1,467,2 6,204	(2022 1,467,2 6,204)	31, 202	3 2022.
2023 2022.			31
		2023 RMB'000	2022 RMB'000
( <u>)/</u> ( <u>)/</u> .		(783,258)	727,425
		Year ended Dece 2023	ember 31, 2022
<u> </u>			
, -	•	1,467,296,204	1,467,2 6,204

#### 10. Trade and Bills Receivables

		2023 RMB'000	2022 RMB'000
₩		1,300,441 3,182 (40,039)	1,712,557 8,118 (114,464)
1008		1,263,584	1,606,211
,	₩		
	•	<b>⊠</b> /	
	84∕	, ₩	,
		2023 RMB'000	2022 RMB'000
1 1 2		1,250,716 29,080	1,601, 07 22,566
2 3		10,992 12,835	6 ,085 27,117
		1,303,623	1,720,675
<b>⊠</b> /		(40,039)	(114,464)
		1,263,584	1,606,211
	₩		₩
		2023 RMB'000	2022 RMB'000
	,	114,464 712	86,2 48,858
. 84⁄		(76,268) 1,131	(23,841) 3,148
		40,039	114,464


#### 11. Trade Payables

11.	Trade Payables		
		2023	2022
		RMB'000	RMB'000
		302,223	427,433
	_	,	
	, ⊠		
		2023	2022
		RMB'000	RMB'000
	<b>\</b> 1	299,729	424,520
	<b>™</b> 2	355	548
	2 3	445	1,373
	3	1,694	2
		302,223	427,433
		30	0 .
12.	Dividends		
		31	2023. (2022
	1.0 ).		
13.	Share Capital		
101	Similar Cupitur	2023	2022
		RMB'000	RMB'000
	1,467,2 6,204 (2022 1,467,2 6,204)	1,467,296	1,467,2 6

## Use of Proceeds from the H Share Listing of the Company

			Listing Date ), Net Proceeds )	3,538.4	24, 2020
	( 1,061.5	Prospectus ),	30%	•	(
M	1,061.5	,	30%		(
1231	,	20%	(		707.7
	·	(	707.7	)	20%
	20.	, 2023,	( Annound	cement )	
<b>⊠</b> ⁄	861.	,		⊠v	, ™
	<b>™</b>		15, 202 704.3	23.	31, 2023,

Significan	t Inve	stments Held					M	
5%		,			-		<b>M</b> √	,
Material A	Acquis	itions and Disp	osals of S	Subsidiaries,	Asso	ciates and	Joint Ve	ntures
		,	•					
Employee	and R	emuneration P	olicy					
<b>⊠</b> /	<b>⊠</b> ⁄	31, 2023,	•	2,080		, <b>M</b>		
		744.4	(2022	, ( .		, 774.4	).	) 🖼
Purchase,	Sale o	r Redemption (	of Listed	Securities				
		,						
. ,	,							
Complian	ce witl	n Corporate Go	vernance	Code				
Corporat	te Gov	ernance Code	) .	2 ₩	1		Rules ).	
 -		, ⊠⁄	•	-	-			
	<b>⊠</b> ′						<b>⊠</b> /	
Final Divi	dend							
).				, 31, 2023 (20	022	1.0		



Sco	pe of Work o	f Ernst & Y	oung ,				
	•	•	,	,	, ,	31, 2023	, & ,
<b>M</b> /		&					•
	& .	•			•		
Eve	ents after the	Reporting I	Period				
<b>M</b> /	⊠' - ⊠'			,	14, 2024,		<b>M</b> ,
. ( .		• ,	11.74	)	•		8 ,80 ,600
		•		15, 2	2024.	,	
Pub	olication of A	nnual Repo	rt				
(	// <b>S</b> SV <b>S</b> SV <b>S</b> SV .	. <u>/</u> )			<b>M</b>	//\dag{\dag{\dag} \dag{\dag{\dag}} \dag{\dag{\dag}} .	<u>M</u> ).
		<b>⊠</b> /	2023 ₩				
App	oreciation						
	,	, ⊠′.	, ⊠⁄				
-		•					
			Shenzhei	n Hepalin	k Pharmaceu Li Li	tical Gro	oup Co., Ltd.

# Chairman

, 28, 2024

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.